Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation
Executive Summary
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.
You may also be interested in...
Gilead Turns Back To Virology With $1.4bn MYR Acquisition
MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.
O’Day Lays Out Plan For Gilead’s Continued HIV Dominance
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
AstraZeneca Collaboration With Medical Research Council May Mean New Life For 22 Compounds
U.K.-based academic research teams will be able to apply to work with the AstraZeneca compounds free of charge and receive grant funding from MRC under the collaboration.